Oncept IL-2

RSS
Authorised

This medicine is authorised for use in the European Union

feline interleukin-2 recombinant canarypox virus (vCP1338 virus)
MedicineVeterinaryAuthorised
  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

Oncept IL-2 is a veterinary medicine that contains the active substance feline interleukin-2 recombinant canarypox virus (vCP1338). It is available as a lyophilisate (freeze-dried pellet) and solvent (water for injections) that are made up into a suspension for injection.

Oncept IL-2 is used to treat cats with fibrosarcoma, a type of aggressive tumour that affects the soft tissues. It is used in combination with surgery and radiotherapy to reduce the risk of and delay the tumour coming back. Oncept IL-2 is used when the size of the tumour is between 2 and 5 cm in diameter and there is no spread of the cancer to other parts of the body.

Treatment with Oncept IL-2 should begin the day before radiotherapy and preferably within one month of the removal of the tumour by surgery. A course of treatment consists of six doses of 1 ml, the first four given at intervals of one week, and the last two at two-week intervals. Each dose is divided into five injections (of approximately 0.2 ml each) under the skin around the site of the surgically removed tumour.

Oncept-IL2 is an immunomodulating agent, which means that it affects the activity of the immune system (the body’s natural defences). The active substance in Oncept IL-2 is a ‘carrier’ canarypox virus that contains the gene to produce the protein feline interleukin-2 (IL-2). IL-2 works by stimulating some of the specialised cells of the immune system to attack the cancer cells. This is expected to kill the cancer cells.

The virus allows the production of IL-2 in small amounts and for a prolonged time at the injection site. Canarypox viruses do not spread or multiply in cats or other mammals. Oncept-IL2 is produced by a method known as ‘recombinant DNA technology’: it contains viruses that have received a gene (DNA), which makes them able to produce IL-2.

Oncept IL-2 was studied in two field studies involving 71 cats that had spontaneously developed fibrosarcoma that had not spread to other parts of the body. The two studies compared a total of 48 cats treated with Oncept IL-2 with 23 control cats that just received surgery and radiotherapy. The main measure of effectiveness was the time until the tumours came back or spread (relapse).

The studies showed that in cats treated with Oncept IL-2 the tumours took longer to come back (over 730 days based on the mid value of the range) compared with control cats (287 days). Oncept IL-2 reduced the risk of relapse in the period from six months after the start of treatment by approximately 56% after one year and 65% after two years.

Side effects that may be seen with Oncept IL-2 treatment are short lived apathy (lack of responsiveness) and hyperthermia (increased body temperature above 39.5°C from the normal value of 38 to 38.5°C).

A moderate reaction at the injection site may occur that involves signs of pain when the area is touched, swelling and scratching. It usually disappears spontaneously within one week.

If the product is accidentally self-injected, medical advice should be sought immediately and the package leaflet or label shown to the doctor.

The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Oncept IL-2 exceed the risks for the approved indication and recommended that Oncept IL-2 be given a marketing authorisation. The benefit / risk balance may be found in the scientific discussion module of this EPAR.

The European Commission granted a marketing authorisation valid throughout the European Union for Onept IL-2 on 3 May 2013. Information on the prescription status of this product may be found on the label / outer package.

български (BG) (132 KB - PDF)

View

español (ES) (103.31 KB - PDF)

View

čeština (CS) (106.93 KB - PDF)

View

dansk (DA) (79.52 KB - PDF)

View

Deutsch (DE) (81.03 KB - PDF)

View

eesti keel (ET) (103.16 KB - PDF)

View

ελληνικά (EL) (132.33 KB - PDF)

View

français (FR) (82.27 KB - PDF)

View

italiano (IT) (79.54 KB - PDF)

View

latviešu valoda (LV) (101.63 KB - PDF)

View

lietuvių kalba (LT) (103.92 KB - PDF)

View

magyar (HU) (100.41 KB - PDF)

View

Malti (MT) (104.22 KB - PDF)

View

Nederlands (NL) (79.68 KB - PDF)

View

polski (PL) (108.29 KB - PDF)

View

português (PT) (123.69 KB - PDF)

View

română (RO) (127.11 KB - PDF)

View

slovenčina (SK) (126.52 KB - PDF)

View

slovenščina (SL) (96.59 KB - PDF)

View

Suomi (FI) (102.04 KB - PDF)

View

svenska (SV) (100.09 KB - PDF)

View

Product information

български (BG) (295.45 KB - PDF)

View

español (ES) (176.47 KB - PDF)

View

čeština (CS) (266.23 KB - PDF)

View

dansk (DA) (189.8 KB - PDF)

View

Deutsch (DE) (200.47 KB - PDF)

View

eesti keel (ET) (186.62 KB - PDF)

View

ελληνικά (EL) (280.61 KB - PDF)

View

français (FR) (179.37 KB - PDF)

View

hrvatski (HR) (255.5 KB - PDF)

View

íslenska (IS) (192.83 KB - PDF)

View

italiano (IT) (185.31 KB - PDF)

View

latviešu valoda (LV) (287.67 KB - PDF)

View

lietuvių kalba (LT) (281.64 KB - PDF)

View

magyar (HU) (261.97 KB - PDF)

View

Malti (MT) (303.92 KB - PDF)

View

Nederlands (NL) (180.99 KB - PDF)

View

norsk (NO) (194.69 KB - PDF)

View

polski (PL) (276.57 KB - PDF)

View

português (PT) (178.94 KB - PDF)

View

română (RO) (278.61 KB - PDF)

View

slovenčina (SK) (281.2 KB - PDF)

View

slovenščina (SL) (264.32 KB - PDF)

View

Suomi (FI) (185.1 KB - PDF)

View

svenska (SV) (177.2 KB - PDF)

View
Latest procedure affecting product information: IG/1279
14/08/2020

български (BG) (57.98 KB - PDF)

View

español (ES) (43.02 KB - PDF)

View

čeština (CS) (55.51 KB - PDF)

View

dansk (DA) (45.46 KB - PDF)

View

Deutsch (DE) (55.2 KB - PDF)

View

eesti keel (ET) (54.99 KB - PDF)

View

ελληνικά (EL) (58.8 KB - PDF)

View

français (FR) (42.8 KB - PDF)

View

íslenska (IS) (33.45 KB - PDF)

View

italiano (IT) (45.67 KB - PDF)

View

latviešu valoda (LV) (82.85 KB - PDF)

View

lietuvių kalba (LT) (50.91 KB - PDF)

View

magyar (HU) (55.46 KB - PDF)

View

Malti (MT) (56.86 KB - PDF)

View

Nederlands (NL) (43.42 KB - PDF)

View

norsk (NO) (53.67 KB - PDF)

View

polski (PL) (68.4 KB - PDF)

View

português (PT) (43.22 KB - PDF)

View

română (RO) (81.32 KB - PDF)

View

slovenčina (SK) (56.89 KB - PDF)

View

slovenščina (SL) (51.25 KB - PDF)

View

Suomi (FI) (44.1 KB - PDF)

View

svenska (SV) (40.86 KB - PDF)

View

Product details

Name of medicine
Oncept IL-2
Active substance
Canarypox virus, strain vCP1338, expressing feline interleukin-2 gene, Live
International non-proprietary name (INN) or common name
feline interleukin-2 recombinant canarypox virus (vCP1338 virus)
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) code
QL03AX

Pharmacotherapeutic group

  • ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  • Immunostimulants
  • Immunostimulants

Therapeutic indication

Immunotherapy to be used in association with surgery and radiotherapy in cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement, to reduce the risk of relapse and increase the time to relapse (local recurrence or metastasis).

Authorisation details

EMA product number
EMEA/V/C/002562
Marketing authorisation holder
Boehringer Ingelheim Vetmedica GmbH

55216 Ingelheim am Rhein
Germany

Marketing authorisation issued
03/05/2013
Revision
5

Assessment history

This page was last updated on

Share this page